Clear Eyes Eye Drops Recalled Nationwide Over Sterility Concerns

The U.S. Food and Drug Administration (FDA) has issued a recall for nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops, citing potential contamination risks. Medtech Products, a subsidiary of Prestige Consumer Healthcare based in New York, voluntarily initiated the recall after concerns emerged regarding the sterility of the product.

Nationwide Distribution Raises Concerns

The affected eye drops, packaged in 0.5-fluid-ounce bottles, were distributed across the United States through major retailers such as CVS and Walmart. The recall, which began on July 29, 2026, encompasses 39,060 products from Lot 2552A, identified by recall number D-0766-2026. These products carry an expiration date of September 30, 2027.

The FDA has categorized this recall as Class II, indicating that exposure to the product could result in temporary or medically reversible adverse health consequences. Despite the recall, no injuries or adverse health effects have been reported to date.

Company Response and Consumer Guidance

Prestige Consumer Healthcare has not yet commented on the recall. Consumers who have purchased the affected eye drops are advised to discontinue use immediately and return them to the place of purchase for a refund. The FDA notice emphasized the importance of ensuring product sterility, a critical factor in preventing eye infections and other potential health issues.

The recall highlights the challenges companies face in maintaining high standards of quality control, especially for products affecting sensitive areas such as the eyes. As investigations continue, the FDA and Medtech Products are working to address the sterility concerns and ensure consumer safety.

Impact on Retailers and Market

Major retailers, including CVS and Walmart, are collaborating with the FDA and Medtech Products to remove the recalled items from their shelves. The recall underscores the importance of vigilance in product distribution and quality assurance processes. Retailers are expected to communicate with consumers who may have purchased the affected products, providing guidance on returns and refunds.

This incident serves as a reminder of the critical role regulatory bodies play in safeguarding public health. The FDA continues to monitor the situation and will provide updates as more information becomes available. Consumers are encouraged to stay informed through official FDA channels and retailer communications.